AI in Genomics Market By Technology (Machine Learning, Deep Learning, Natural Language Processing), By Application (Drug Discovery, Genomic Sequencing, Genetic Research & Personalized Medicine, Biomarker Discovery), By End-Use Industry (Healthcare Providers, Pharmaceutical & Biotech Companies, Contract Research Organizations), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the AI in Genomics Market was valued at USD 3.2 billion in 2023 and will surpass USD 13.0 billion by 2030; growing at a CAGR of 22.0% during 2024 - 2030.

The AI in genomics market is evolving rapidly, driven by the integration of artificial intelligence technologies in genomic research and biotechnology. AI tools such as machine learning, deep learning, and natural language processing are transforming genomics by enhancing the analysis of vast genomic datasets, enabling researchers to uncover insights at an unprecedented scale and speed. From drug discovery and genomic sequencing to genetic research and personalized medicine, AI technologies are facilitating breakthroughs that were once unimaginable. The market for AI in genomics is set to grow significantly as AI accelerates the pace of genomic research and helps unlock the potential of personalized medicine, targeted therapies, and advanced diagnostics.

As the AI in genomics market continues to expand, several key subsegments within the technology, application, and end-use industry categories are emerging as key drivers of this growth. Understanding these subsegments and their dynamics will be crucial for stakeholders looking to capitalize on the opportunities in this transformative field. Below, we explore the largest and fastest-growing subsegments within each category.

Machine Learning Segment Is Largest Owing to Its Versatility in Genomic Data Analysis

Machine learning (ML) is the largest technology subsegment in the AI in genomics market due to its versatility and effectiveness in genomic data analysis. ML algorithms can process vast amounts of genomic data, identify patterns, and predict outcomes, making them invaluable in various applications such as genomic sequencing, drug discovery, and personalized medicine. By learning from historical datasets, ML models improve the accuracy of predictions and accelerate the identification of genetic markers associated with diseases, enabling more targeted and effective treatments.

ML’s ability to handle complex, high-dimensional data makes it the dominant technology in genomics. It is particularly well-suited for tasks such as gene expression analysis, mutation detection, and variant interpretation. As the volume of genomic data continues to increase with advances in sequencing technologies, the role of ML in analyzing and interpreting this data will only grow, cementing its position as the largest technology subsegment in the AI in genomics market.

Drug Discovery Application Is Largest, Powered by AI’s Impact on Precision Medicine

In the application category, drug discovery is the largest subsegment, largely due to the significant impact AI has on the development of precision medicine. AI technologies, including machine learning and deep learning, are transforming drug discovery by identifying new drug candidates, predicting molecular behavior, and optimizing clinical trial designs. By leveraging genomic data, AI models can simulate the effects of various compounds on specific genetic profiles, enabling the development of targeted therapies that are more effective and have fewer side effects.

The use of AI in drug discovery also accelerates the development timeline, reduces costs, and improves the chances of clinical success. With the growing emphasis on personalized medicine—treatments tailored to an individual's genetic makeup—AI’s ability to integrate genomic data with clinical information has made it an indispensable tool in the drug discovery process. This has positioned drug discovery as the largest and most critical application in the AI in genomics market.

Pharmaceutical & Biotech Companies Segment Is Largest End-Use Industry, Leading AI Adoption

Pharmaceutical and biotechnology companies represent the largest end-use industry in the AI in genomics market. These companies are leading the adoption of AI technologies to enhance their R&D capabilities, particularly in drug discovery, genetic research, and personalized medicine. Pharmaceutical and biotech firms are leveraging AI to analyze genomic data, identify genetic biomarkers, and develop therapies that are more targeted and effective. AI is also playing a key role in optimizing clinical trials, from patient recruitment to monitoring treatment responses.

The growing demand for personalized medicine and the ability to offer more tailored therapies is driving the adoption of AI in these industries. As pharmaceutical and biotechnology companies strive to accelerate their drug discovery processes and improve the success rates of clinical trials, AI technologies are helping them stay ahead of the competition. This makes pharmaceutical and biotech companies the largest user group of AI in genomics, with their ongoing investment in AI driving the market's growth.

North America Is Largest Region, Dominated by Innovation and Research Investment

North America is the largest region in the AI in genomics market, primarily driven by the high levels of investment in genomics research and biotechnology innovations. The United States, in particular, is a leader in AI integration within genomics, with major biotech hubs like Silicon Valley and Boston at the forefront of this trend. The presence of top-tier universities, research institutions, and leading pharmaceutical companies in North America has fostered a strong ecosystem for AI-driven genomic research and applications.

In addition, government funding and initiatives such as the Precision Medicine Initiative and the National Institutes of Health (NIH) investments in AI research have further propelled the region's dominance. North America is expected to remain the largest region in the AI in genomics market due to its established infrastructure, high research spending, and a robust regulatory environment that supports technological advancements in the field.

Leading Companies and Competitive Landscape

The competitive landscape of the AI in genomics market features a mix of well-established pharmaceutical giants and cutting-edge AI-focused biotech companies. Leading companies such as IBM Watson Health, Illumina, Thermo Fisher Scientific, and Google Health are at the forefront of integrating AI into genomic research. IBM, for instance, has been instrumental in applying AI to drug discovery and genomic data analysis, while Illumina has leveraged AI in next-generation sequencing technologies. Google Health, through its DeepMind division, is also making significant strides in applying AI to protein folding and genetic research.

Recent Developments:

• Illumina has announced the launch of a new AI-based platform for faster and more accurate genomic sequencing, aimed at improving precision medicine.
• Thermo Fisher Scientific unveiled a new AI-powered genomic analytics tool to enhance the interpretation of sequencing data for personalized treatments.
• IBM Watson Health has expanded its AI-driven genomics platform to include predictive analytics for genetic disease detection and drug development.
• Tempus has entered into a strategic collaboration with Grail to integrate AI in genomics for early cancer detection and personalized treatment solutions.
• Insilico Medicine has introduced an AI-powered drug discovery platform that uses genomic data to accelerate the development of targeted therapies.

List of Leading Companies:

• Agilent Technologies
• BenevolentAI
• Bristol-Myers Squibb
• Deep Genomics
• Freenome
• Genpact
• Grail
• IBM Watson Health
• Illumina
• Insilico Medicine
• Qiagen
• Tempus
• Thermo Fisher Scientific
• Veracyte
• XtalPi

Report Scope: